Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer

Ducoulombier, Simon; Golfier, François; Colomban, Olivier; Benayoun, David; Bolze, Pierre‐Adrien; Tod, Michel; You, Benoît

doi:10.21873/anticanres.12150

Cited by 6 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA125 is currently the most widely used tumor marker for the diagnosis of EOC [ 7 , 30 – 32 ]. It is a glycoprotein with a molecular weight of 200 000, encoded by the MUC16 gene.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma

Yin

Ren

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

Background This study aimed to investigate the value of CA125 dynamic change in PFS prediction for patients with epithelial ovarian carcinoma (EOC). Material/Methods Data analysis was performed using SPSS 24.0 statistical software with progression-free survival (PFS) as an outcome measure. Kaplan-Meier method was used to analyze the relationship between PFS and preoperative and postoperative NLR, PLR and CA125 levels, CA125 half-life, CA125-negative time, age, FIGO stage, histopathology, differentiation, vessel carcinoma embolus, and ascites. The survival curves were compared by the log-rank test. Based on the results of single-factor analysis, the Cox model was used for multifactor analysis to analyze independent risk factors affecting the PFS of epithelial ovarian carcinoma. Results A total of 117 patients with EOC were selected from January 2012 to January 2019 to carry out a retrospective study. Univariate analyses showed that PFS of the patients with EOC was associated with differentiation, vessel carcinoma embolus, FIGO stage, CA125 half-life, CA12-negative time, and preoperative NLR (P<0.05). Multivariate analysis by the Cox model showed that vessel carcinoma embolus, CA125 half-life, differentiation, and preoperative NLR are the independent risk factors for PFS in patients with EOC. Conclusions The serum CA125 dynamic as reflected by CA125 half-life is the most important independent prognostic factor in patients with EOC. The simplicity of CA125 monitoring and its correlation with EOC patient survival can identify patients with poor prognosis through monitoring CA125 half-life, which can provide a reference value for use in clinical practice.

show abstract

“…CA125 is currently the most widely used tumor marker for the diagnosis of EOC [ 7 , 30 – 32 ]. It is a glycoprotein with a molecular weight of 200 000, encoded by the MUC16 gene.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma

Yin

Ren

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…The first study published in 2017 by Ducoulombier et al [28] was a retrospective cohort of 54 patients, which showed that the KELIM score was an independent predictor for optimal cytoreduction after neoadjuvant chemotherapy. This result is in accordance with our findings, but with a key difference in the main endpoint, which was complete and not optimal debulking surgery.…”

Section: Discussionmentioning

confidence: 99%

The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer

Zouzoulas,

Tsolakidis,

Tzitzis

et al. 2024

Cancers

View full text Add to dashboard Cite

(1) Background: Neoadjuvant chemotherapy followed by interval debulking surgery is used in the treatment of advanced ovarian cancer. However, no tool can safely predict if complete cytoreduction after 3–4 cycles can be achieved. This study aims to investigate if the KELIM score can be a triage tool in the identification of patients that will be ideal candidates for interval debulking surgery (IDS). (2) Methods: We retrospectively analyzed the records of patients with high-grade serous advanced ovarian cancer that were treated in the 1st Department of Obstetrics–Gynecology, 2012–2022, with neoadjuvant chemotherapy followed by IDS. Patient characteristics, oncological outcome and follow-up information were collected. The primary outcome was the association of the KELIM score with residual disease. (3) Results: 83 patients were categorized into two groups: Group A (51 patients) with favorable (≥1) and Group B (32 patients) with unfavorable (<1) KELIM scores. A statistically significant correlation between KELIM and residual disease (p < 0.05) exists, showing that patients with a favorable KELIM score can achieve a complete IDS. Furthermore, there was a statistically significant difference in overall survival (p = 0.017), but no difference was observed in progression-free survival (p = 0.13); (4) Conclusions: KELIM seems to safely triage patients after neoadjuvant chemotherapy and decide who will benefit from IDS.

show abstract

“…The large intra-individual and interindividual variability of miRNA time-changes made any longitudinal assessment impossible with mathematical modeling. As a consequence, it was not adequate to search for relationships between tumor burden alterations and miRNA kinetics using mathematical modeling, contrarily to what was done with CA125 [3,[29][30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Robelin

Tod

Colomban

et al. 2020

Gynecologic Oncology

View full text Add to dashboard Cite

Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer

Abstract: We identified CA-125 modeled kinetic parameters during neoadjuvant chemotherapy harboring potential predictive values regarding the likelihood of optimal cytoreduction, along with time to second-line chemotherapy in optimally-cytoreduced patients.

Cited by 6 publications

References 26 publications

Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma

Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma

The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer

Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Contact Info

Product

Resources

About